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Introduction
 Oral squamous cell carcinoma (OSCC) ranks among 
the top ten most common cancers worldwide (Stewart 
and Kleihues, 2008; Rao et al., 2013). The survival rate 
for OSCC has remained generally unchanged in the past 
three decades due to late detection despite the curious 
fact that the oral cavity can be readily examined (Neville 
and Day, 2002; Rao et al., 2013). One promising strategy 
for the treatment of OSCC and other cancers, which has 
developed as a result of breakthrough in the fields of 
molecular biology, cancer genetics, and cancer biology, 
is molecular targeted therapy (Sahu and Grandis, 2011). 
These molecular markers are also being explored for use 
in developing clinical diagnostic aids, detecting malignant 
cells in biopsies, predicting recurrence at tumour surgical 
margins, diagnosing unsuspected nodal metastasis and to 
serve as adjuncts to routine histopathological examination 
to aid prognostication and effective management (Scully 
and Bagan, 2009). Some biomarkers are already being 
used as clinical tools but it is still in a juvenile stage, hence 
the need for more biomarkers to be developed (Balan et 
al., 2010). 
 Cadherins are a class of type-1 trans-membrane 
1Department of Oro-Maxillofacial Surgical and Medical Sciences, 2Oral Cancer Research and Coordinating Center, Faculty of 
Dentistry, University of Malaya, Kuala Lumpur, 3Department of Oral & Maxillofacial Surgery, Hospital Tengku Ampuan Rahimah, 
Selangor, Malaysia  *For correspondence: swuichan@gmail.com
Abstract
 Background: The survival rate for oral squamous cell carcinoma (OSCC) has remained generally unchanged 
in the past three decades, underlining the need for more biomarkers to be developed to aid prognostication and 
effective management. The prognostic potential of E-cadherin expression in OSCCs has been variable in previous 
studies while galectin-9 expression has been correlated with improved prognosis in other cancers. The aim of 
the present study was to investigate the expression of galectin-9 and E-cadherin in OSCC and their potential 
as prognostic biomarkers. Materials and Methods: E-cadherin and Galectin-9 expression was examined by 
immunohistochemistry in 32 cases of OSCC of the buccal mucosa (13 with and 19 without lymph node metastasis), 
as well as 6 samples of reactive lesions and 5 of normal buccal mucosa. Results: The expression of E-cadherin in 
OSCC was significantly lower than the control tissues but galectin-9 expression was conversely higher. Median 
E-cadherin HSCOREs between OSCCs positive and negative for nodal metastasis were not significantly different. 
Mean HSCOREs for galectin-9 in OSCC without lymph node metastasis (127.7±81.8) was higher than OSCC with 
lymph node metastasis (97.9±62.9) but this difference was not statistically significant. Conclusions: E-cadherin 
expression is reduced whilst galectin-9 expression is increased in OSCC. However, the present results suggest 
that E-cadherin and galectin-9 expression may not be useful as prognostic markers for OSCC. 
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proteins known for its calcium-dependent cell-cell 
adhesion property (Marsh and Brackenbury, 1996). 
E-cadherins are members of this protein family found in 
epithelial cells which serve important roles in cell adhesion 
by ensuring that cells within tissues are bound together 
(Alberts et al., 2002). The loss of E-cadherin function or 
expression has been implicated in cancer progression and 
metastasis (Christofori and Semb, 1999). 
 Galectins are a family of beta-galactoside-binding 
proteins (Leffler et al., 2004) which are generally 
present in the cytoplasm and in the nucleus as well as 
extracellularly on the cell surface and especially within 
the extracellular matrix (Cooper and Barondes, 1999). 
Galectin-9 was identified as a potent T cell derived 
eosinophil chemoattractant (Matsumoto et al., 1998). 
Since eosinophil accumulation has been linked to a 
better prognosis for OSCC (Dorta et al., 2002), it is 
hypothesized that expression of Galectin-9 is related to a 
better prognosis (Hirashima, 2003). In addition, Galectin-9 
induces adhesion and aggregation of certain cell types and 
can be a prognostic factor in patients with melanoma and 
breast cancer (Hirashima, 2003). 
 Although the prognostic potential of E-cadherin 
expression has been widely studied, conflicting results 
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cast doubts over its reliability and hamper its recognition 
as a biomarker. Galectins are a group of promising and 
relatively untapped source in the exhaustive quest for 
potential biomarkers in cancers. Galectin-9 expression 
has already been correlated with improved prognosis in 
malignant melanoma and breast cancer. The aim of this 
study was to investigate the expression of Galectin-9 and 
E-cadherin in OSCC and their potential as prognostic 
markers. 
Materials and Methods
Study design
 The present study was a cross-sectional study 
investigating the expression of E-cadherin and Galectin-9 
in OSCC in comparison to epithelium of normal 
mucosa and reactive lesions. Expression of E-cadherin 
and Galectin-9 was also compared in OSCC with and 
without lymph node involvement. Ethical clearance 
was duly obtained from the relevant authorities: DF 
OP1008/0043(P).
Tissue samples
 Formalin-fixed paraffin-embedded (FFPE) tumour 
tissues of histologically diagnosed cases of OSCC were 
obtained from the archives of the Department of Oro-
Maxillofacial Surgical and Medical Sciences and Oral 
Cancer Research and Coordinating Center (OCRCC). 
Clinicopathological details of all suitable cases were 
recovered from the departmental registry and reviewed. 
Available samples from the year 2000 till June 2012 which 
satisfied all inclusion criteria were selected. 
Inclusion criteria
 Our study group consisted of cases of primary OSCC 
which had not undergone radiotherapy or chemotherapy, 
as evidenced by previous biopsy reports or clinical notes. 
This was to avoid therapy-induced changes which would 
have interfered with targeted tumour cells in subsequent 
immunohistochemical staining (Suzuki et al., 2004; 
Schneider et al., 2005). Any previous treatment would 
also have altered normal lymphatic drainage, resulting in 
unusual distribution of regional spread of disease (Edge 
et al., 2010).
 Only OSCCs of the buccal mucosa were chosen as 
an attempt to standardize samples because prognosis 
as indicated by the involvement of lymph nodes may 
change according to different tumour sites (Woolgar, 
2006). Buccal mucosa refers to all membranous lining 
of inner surface of the cheeks and lips from the line of 
contact between opposing lips to the line of attachment 
of mucosa of the alveolar ridge (upper and lower) and 
pterygomandibular raphe (Edge et al., 2010). Degree of 
differentiation was not emphasized because histological 
grade alone is weakly correlated to outcome (Woolgar, 
2006).
 Excisional biopsies or surgically removed specimens 
of OSCC with report on lymph node involvement (when 
relevant) were selected because the prognostic importance 
of presence or absence of lymph node metastasis, which 
is the focus of our study, has been recognized for decades 
(Woolgar, 2006).
Exclusion criteria
 Cases with incomplete or ambiguous documented 
evidence for the above inclusion criteria were excluded.
 
Sample size
 PS (Power and Sample Size Calculation) Software 
Version 3.0.43 was used to calculate the sample size for 
this study. Based on the expected mean difference for 
immunostaining score between patients with and without 
lymph node metastasis of 53 (Li et al., 2012), at least 23 
cases in each sample group would be needed to be able to 
reject the null hypothesis that the staining score means of 
both sample groups are equal with the probability (power) 
of 0.8 (80%). The Type I error probability associated with 
this test of the null hypothesis is 0.05 (p=0.05).
 In fact, based on previous studies in which sample size 
ranged from 8 (Yamada et al., 1997) to 83 (Liu et al., 2010) 
for E-cadherin and 9 (Pioche-Durieu et al., 2005) to 65 
(Alves et al., 2011) for Galectin-9, significant difference 
was elicited in samples as small as 30 (Mahomed et 
al., 2007). Due to various constraints, only 34 OSCC 
cases which fulfilled the above criteria were available 
when this research was initiated. Of these, 14 cases 
exhibited positive lymph node metastasis and 20 without 
metastasis. However, two cases had to be excluded after 
the immunohistochemical staining because the amount of 
tissue remaining was inadequate to allow assessment of 
our markers. 
 Therefore at final count, our sample groups were as 
follows: i) 13 OSCC cases with lymph node metastasis; 
ii)19 OSCC cases without lymph node metastasis; 
iii) 6 samples of oral mucosa from reactive lesions 
(fibroepithelial polyp); iv) 5 samples of normal buccal 
mucosa (taken with consent from patients undergoing 
surgical removal of impacted third molar) 
Antibodies
 Dako monoclonal mouse anti-human antibody against 
E-cadherin, clone NCH-38 (DAKO Mo a hu E-Cadherin, 
clone NCH-38) and Abcam rabbit polyclonal antibody to 
Galectin-9 were purchased from Bita Lifescience Sdn Bhd 
with PPP grant P0035/2010B.
Immunohistochemical staining
 Immunohistochemical (IHC) staining was performed 
with antibodies to Galectin-9 and E-cadherin by the 
Immunoperoxidase Envision technique on sections of 
FFPE tissues from the above mentioned sample groups. 
Optimization was achieved for Galectin-9 at 1:1000 
dilution and E-cadherin at 1:100 dilution with Dako 
REALTM Antibody Diluent.
 Sections were heated at 60oC for 1 hour in the 
microwave oven after which they were deparaffinized in 
xylene and rehydrated in graded ethanol according to the 
standard procedure. Antigen retrieval was performed by 
incubating sections immersed in Tris-EDTA at pH 9.0 in 
a decloaking chamber at 121oC for 30 seconds after which 
the sections were left to cool at room temperature for 20 
minutes before they were washed in running tap water for 
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5 minutes.
 Sections were subjected to endogenase peroxidase 
blocking with Dako REALTM Peroxidase-Blocking 
Solution for 10 minutes in a humidified chamber. Sections 
were later washed in 2 baths of Phosphate Buffered Saline 
pH 7.4 (PBS). Next, sections were incubated with primary 
antibodies (antibodies to E-cadherin or Galectin-9) for 30 
minutes at room temperature. 
 After the requisite PBS rinse, sections were incubated 
in a second antibody and subsequently staining was 
visualized using the Dako REALTM EnVisionTM Detection 
System, Peroxidase/DAB+, Rabbit/Mouse kit. The 
photosensitive 3,3’-diaminobenzidine (DAB) forms a 
brown end product upon oxidation at the site of target 
antigen, which is interpreted as positive staining. Later, 
sections were washed gently in running water for 5 
minutes.
 Sections were then counterstained with hematoxylin, 
dehydrated in increasing concentrations of ethanol, cleared 
in xylene before they were eventually mounted in DPX 
(Di-N-Butyle Phthalate in Xylene), a synthetic resin 
mounting media.
 Normal oral mucosal tissues were used as positive 
control for E-cadherin and Non-Hodgkin lymphoma (T 
cell lineage) for Galectin-9. For the negative controls, 
primary antibodies were omitted and replaced by TBS 
buffer.
IHC staining evaluation
 The intensity and percentage of stained tumour cells 
in each section were determined independently by two 
observers without prior knowledge of the clinical or 
histopathological data. Before evaluation, a calibration 
exercise was conducted between the two observers to 
reduce inter- and intra- observer discrepancies. The 
immunostaining intensity (Figure 1) was graded 0 for 
no detectable staining, 1 for weak staining, 2 for clearly 
positive staining and 3 for strongly positive staining (Irie 
et al., 2005).
 A semiquantitative index known as the HSCORE 
(histochemical score) (Kageshita et al., 2002) which 
incorporates both intensity and percentage of stained 
cells was used for staining evaluation. H-SCORE is a 
summation of the proportion of cell staining at each 
intensity multiplied by the intensity of the staining 
(Berchuck et al., 1989) represented by the following 
formula (Kitawaki et al., 1999; Liang et al., 2008):
	 HSCORE=∑Pi ( i )
 where i=intensity of staining (0-3) and Pi=percentage 
of stained cells for each given i (0-100%). 
 A total of 500 tumour cells (100 cells each in 5 high 
power fields) were assessed in each section to calculate 
the HSCORE. This score theoretically ranges from a 
minimum of 0 in cases with no staining to a maximum of 
300 in cases where all the tumour cells stain with maximal 
intensity. The final HSCORE is a mean of two values 
calculated by the two independent observers. Differences 
of greater than 10% were resolved by consensus (Berchuck 
et al., 1989). 
Statistical analysis
 Statistical analysis was performed with a series of 
parametric and non-parametric tests using the SPSS 
package (version 15) to investigate the expression of the 
markers (Galectin-9 and E-cadherin) in OSCCs compared 
to control group, as well as association between the 
staining pattern of the markers and the metastatic potential 
of OSCC (lymph node status). A P-value of less than 0.05 
was considered to be statistically significant. 
Results 
Clinicopathological details
 Our OSCC cases had a mean age at presentation 
of 60 years with a range of 36 to 89 years. Of the 32 
patients, an overwhelming majority of 87.5% was female 
and likewise Indians constituted a great percentage at 
81.3%. The histopathological grading in our cases was 
vastly imbalanced with moderately differentiated OSCC 
amounting to 22 cases, 9 cases being well-differentiated 
and only a singular case of poorly differentiated OSCC. 
13 of our cases exhibited positive metastasis to the lymph 
nodes as opposed to 19 without lymph node involvement. 
In addition, there were 11 cases of normal and reactive 
tissues, consisting of 5 normal buccal mucosa and 6 
fibroepithelial hyperplasia (FEH), considered collectively 
as the control group.
Expression of E-cadherin and Galectin-9 in OSCC of 
buccal mucosa in comparison to normal oral mucosa 
and reactive lesions
 Close examination of the epithelium from the control 
Figure 1. Immunostaining Intensity for Galectin-9 (A-
D) and E-cadherin (E-H) is Graded 0 for No Detectable 
Staining (A, E), 1 for Weak Staining (B, F), 2 for 
Clearly Positive Staining (C, G) and 3 for Strongly 
Positive Staining (D, H). [X400 magnification]
Figure 2. Distribution of E-cadherin Expression in 
Epithelium from the Control Group was Concentrated 
at the Basal 2/3 of the Epithelium
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group revealed strong, positive membranous staining for 
E-cadherin at the basal and parabasal layer (Figure 2). 
The staining gradually lost its intensity as it approached 
the superficial spinous layer and the keratotic layer. In 
general, E-cadherin staining comprised approximately the 
basal 2/3 of the epithelium, excluding the basal surface. 
 E-cadherin showed similar membranous staining of 
the tumour islands, especially with better differentiated 
tumour cells. Central parts of tumour islands stained more 
prominently than the peripheral part (Figure 4 A and B). 
 Mann-Whitney test was conducted to compare 
HSCOREs for E-cadherin expression between the control 
group and OSCC because HSCOREs for E-cadherin were 
not normally distributed. E-cadherin expression in OSCC 
was greatly reduced compared to normal epithelium (Table 
1).
 Galectin-9 staining was less predictable but a peculiar 
pattern of staining was noted when examining the surface 
epithelium of fibroepithelial hyperplasias (Figure 3 A and 
B). The spinous layer of the epithelium showed weak 
to moderate positive cytoplasmic and mostly nuclear 
staining for Galectin-9 in areas (Figure 3B), sometimes 
with prominent band-like staining. This pattern was not 
consistent throughout the entire epithelium and was 
less pronounced or absent in the normal buccal mucosa 
samples (Figure 3 C and D). Nonetheless, this could be 
attributed to the limited stretch of epithelium and gross 
inflammation in these normal buccal mucosa samples. 
A faint cytoplasmic staining was also noted along the 
basal cell layer but the staining was too weak and mostly 
disregarded in the HSCORE evaluation. Staining of 
other areas in the epithelium was sporadic with a lack of 
appreciable pattern. 
Galectin-9 staining in neoplastic epithelium seemed to 
concentrate near keratinizing cells (Figure 4 C and D). 
Interestingly, Galectin-9 displayed mostly cytoplasmic 
staining in neoplastic epithelium. 
 Since normality assumption was met, independent 
t-test was conducted to compare Galectin-9 expression 
in OSCC and the control group (Table 2). The HSCOREs 
of OSCC was significantly higher than the control group 
(p=0.000). 
Comparison between expression of E-cadherin and 
Galectin-9 in OSCC with and without lymph node 
metastasis
 Before proceeding with the analyses, all the numerical 
data was checked to determine whether the assumption 
of normal distribution was satisfied. From the tests of 
normality, HSCOREs for E-cadherin were not normally 
distributed. Thus, non-parametric test (Mann-Whitney 
test) was used for analysis involving E-cadherin’s 
HSCOREs. Meanwhile, HSCOREs for galectin-9 were 
normally distributed and therefore were analyzed using 
Figure 3. Distribution of Galectin-9 Staining in 
Fibroepithelial Hyperplasias (A, B) and Normal Buccal 
Mucosa (C, D)
Figure 4. Distribution of E-cadherin (A, B) and 
Galectin-9 (C, D) Staining in Neoplastic Epithelium. 
A) Membranous staining of tumour islands; B) Central parts of 
tumour islands stained more prominently than the peripheral 
part; C) Intense staining of neoplastic islands, particularly near 
keratinizing cells; D) Intracytoplasmic positivity for Galectin-9 
in neoplastic cells
Table 1. Comparing HSCORE for E-cadherin 
Expression between Control Group and OSCC
Variable Control  OSCC  Z statistic* p value**
 (n=11) (n=32)
 Median (IQR) Median (IQR)
E-cadherin 292.3(51) 84.3 (85) -4.7 0.0
*Mann Whitney test was used; **Level of significance is 0.05
Table 2. Comparison of HSCORE for Galectin-9 
between Control Group and OSCC
Variable Control  OSCC Mean diff. t statistic p value
 (n=11) (n=32) (95% CI) (df)
 Median (IQR) Median (IQR)
Galectin-9 38.0 (36.5) 115.6 (75.1) -77.6 (-112.6, -42.7) -4.5 (35.8)* 0.0
*Equal variance not assumed (Levene’s test p value =0.045) Level of significance 
was set at 0.05 
Table 3. Comparing HSCORE for E-cadherin between 
OSCC with Positive (OSCC+) and Negative (OSCC-) 
Lymph Node Involvement
Variable OSCC+  OSCC-  Z statistic* p value**
 (n=13) (n=19)
 Median (IQR) Median (IQR)
E-cadherin 84.2 (96) 84.4 (77) -0.5 0.6
*Mann Whitney test was used; **Level of significance is 0.017
Table 4. Comparison of HSCORE for Galectin-9 
between OSCC with Positive (OSCC+) and Negative 
(OSCC-) Lymph Node Involvement
Variable OSCC+  OSCC- Mean diff. t statistic p value
 (n=13) (n=19) (95% CI) (df)
 Median (IQR) Median (IQR)
Galectin-9 97.9 (62.9) 127.7 (81.8) -29.9 (-84.9, 25.1) -1.1 (30)* 0.3
*Equal variance not assumed (Levene’s test p value =0.045) Level of significance 
was set at 0.05 
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independent t-test.
 Median E-cadherin HSCOREs between OSCC with 
positive nodal metastasis and OSCC with negative nodal 
metastasis were not significantly different (p=0.631) 
(Table 3). Therefore, there was no significant association 
between E-cadherin expression and lymph node status of 
OSCC patients.
 On the other hand, independent t-test (Table 4) 
comparing Galectin-9 staining between means of 
HSCOREs for OSCC in positive and negative lymph 
node involvement were also not significantly different 
(p=0.276). Hence, no significant association was 
observed between Galectin-9 expression and lymph node 
involvement status. 
Discussion
Galectins are generally known to be highly expressed in 
epithelial cells and immune cells. They can be detected in 
keratinocytes, melanocytes, dendritic cells, macrophages 
and T cells in skin. Notably, different galectin members 
may project a different expression pattern in keratinocytes 
(Chen et al., 2012). Whilst expression of galectin-1, -3 and 
-7 have been adequately identified (Saussez et al., 2007; 
Chen et al., 2012), description of Galectin-9 expression 
in epithelial cells has been comparatively lacking. 
Galectin-9 is more commonly localized to thymus, 
T-cells, kidney and Hodgkin’s lymphoma (Rabinovich 
et al., 2002). An early paper by Murase et al. (1985) 
described strong demonstration of lectin-binding sites in 
the stratum spinosum and granulosum, few in the basal 
layer and none in the fully keratinized superficial layer, 
a pattern curiously similar to Galectin-9 expression in 
normal epithelium in our study. However, galectins are 
only one of many lectins (Nakahara and Raz, 2008) and 
it has already been established that other galectins may be 
present in the epithelium. Friedrichs et al. (2007) reported 
that galectin-3 and-9 are the most abundantly expressed 
galectins in Madin-Darby canine kidney (MDCK) cells, a 
commonly used general model for epithelial cells, which 
comprise epithelium. Liang et al. (2008) observed potent 
immunostaining for cytoplasmic Galectin-9 in normal 
squamous epithelial cells of the cervix which appears 
to involve the entire epithelium while Cada et al. (2009) 
reported basal and suprabasal presence of Galectin-9 in 
the epidermis. More relevantly, Fik et al. (2013) described 
expression of Galectin-9 exclusively at the basal layer 
of normal oral epithelium. Pioche-Durieu et al. (2005) 
observed absent or weak staining for Galectin-9 in adjacent 
normal mucosa in fresh nasopharyngeal carcinoma 
biopsies which is more consistent with our normal buccal 
mucosa samples. However, the distinctive yet inconsistent 
staining of the spinous layer in our fibroepithelial polyp 
samples could well be more representative of Galectin-9 
expression in the oral mucosa. This is because the small 
and limited normal buccal mucosa samples in our study 
are insufficient to provide a complete picture. In addition, 
we observed a similar pattern in some of the normal oral 
mucosa adjacent to neoplastic epithelium. The means 
of HSCOREs between these two samples in the control 
group were also not significantly different and therefore, 
considered collectively as a group during statistical 
analysis. 
To the best of our knowledge, there are only three 
reports on Galectin-9 expression in SCC of the head 
and neck (Kasamatsu et al., 2005; Pioche-Durieu et al., 
2005; Fik et al., 2013). Indeed, the paucity of related 
literature discouraged unequivocally drawn conclusions 
about the role of Galectin-9 in head and neck SCC 
biology, unlike that of galectin-1, -3 and 7 (Saussez et al., 
2007; Alves et al., 2011). Kasamatsu et al. (2005) found 
Galectin-9 expression to be downregulated in OSCC cell 
lines while Pioche-Durieu et al. (2005) demonstrated 
intense Galectin-9 expression in the malignant cells of 
nasopharyngeal carcinoma. Fik et al. (2013) documented 
complete absence of Galectin-9 in their analysis of 
62 head and neck SCCs from various locations. In 
contrast, our results show increased expression of 
Galectin-9 in formalin-fixed paraffin-embedded sections 
of OSCC. It is important to note that IHC monitoring of 
clinical specimens is indispensable and possibly more 
advantageous than engineered cell systems in correlation 
studies by accounting for confounding effects (Cada et 
al., 2009). And while our results may seem in agreement 
with Pioche-Durieu et al. (2005), we remain wary as 
involvement of other galectins in tumorigenesis was 
deemed to depend heavily on the histological origin of 
the tissue (Saussez et al., 2007). The obvious disparity 
of Galectin-9 expression in our study compared to other 
studies may be attributed to the difference of tumour 
origin, patients or methodology in each study. Remarkably, 
none of the aforementioned studies analyzed Galectin-9 
expression in SCC of the buccal mucosa. Moreover, the 
use of FFPE tumour tissues in our study instead of fresh 
frozen tissue might also have influenced the antigenicity 
of the samples. 
Honjo et al. (2000) reported that the nuclear expression 
levels of galectin-3 decreased whereas the opposite was 
true for cytoplasmic expression during the progression 
from normal to cancerous state in their analysis of 77 
tongue specimens. In our study, there was a similar shift 
of nuclear staining to cytoplasmic staining for Galectin-9. 
Exclusive cytoplasmic staining has also been reported in 
cancer cells of the breast (Irie et al., 2005) and mostly 
cytoplasmic staining in melanoma cells (Kageshita et 
al., 2002). However, we observed a combination of 
nuclear and cytoplasmic staining for Galectin-9 in the 
superficial layers of the normal mucosa while Honjo 
et al. (2000) described only cytoplasmic staining of the 
superficial / parasuperficial layer with nuclear staining 
concentrated at the basal / parabasal layers for galectin-3. 
Our study shares another similarity with galectin-3 
in which staining for Galectin-9 involves the tumour 
cells near the keratinized areas (Saussez et al., 2007). 
The dissociated expression of cytoplasmic and nuclear 
Galectin-9 during OSCC progression suggests different 
biological roles for Galectin-9 depending on its subcellular 
localization (Honjo et al., 2000), especially since it 
has been established that galectins may segregate into 
various cellular compartments depending on the cellular 
status (Saussez et al., 2007). The precise functional 
role of Galectin-9 in the cytoplasm and association of 
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cytoplasmic expression with surface expression have yet 
to be clarified (Kageshita et al., 2002; Irie et al., 2005). In 
this context, it is noteworthy that galectin can influence 
cell proliferation and apoptosis from the cell surface and 
also from intracellular sites (Smetana et al., 2006).
Galectin-9 expression in tumour cells is associated 
with a better prognosis in cervical SCC (Liang et al., 
2008), melanoma and breast carcinoma (Hirashima et 
al., 2004). Irie et al. (2005) suggested that Galectin-9 
suppresses metastasis in multisteps by inhibiting invasion 
to extracellullar matrix, detachment from tumours, and 
attachment to vascular endothelium. Even though our 
results were not significant, there is a trend of higher 
means for Galectin-9 HSCOREs in OSCC without lymph 
node metastasis compared to OSCC with positive lymph 
node metastasis. Since negative lymph node involvement 
denotes a better prognosis, higher Galectin-9 HSCOREs 
in our study would also indicate an improved prognosis. 
Additional studies are warranted because an inverse 
relationship of Galectin-9 expression with occurrence 
of distant metastasis but not lymph node metastasis in 
breast carcinoma has been reported (Irie et al., 2005). In 
fact, a crosscheck of our department database revealed 
that two of our OSCC cases with negative lymph node 
involvement eventually developed recurrence, indicating 
perhaps future studies should consider the correlation of 
Galectin-9 expression with variables such as recurrence 
rate, distant metastasis or survival rate.
The distribution of E-cadherin expression in normal 
epithelium in our study is less contentious and supported 
by various studies reported in the literature (Yamada et al., 
1997; Diniz-Freitas et al., 2006; Mahomed et al., 2007; 
Zhong et al., 2007; Wang et al., 2009; Rosado et al., 2013). 
Also in conformance to these studies is the heterogenous 
E-cadherin expression in invasive OSCC, with a 
distinctive pattern at the advancing edge. Invasive tumour 
front (ITF) which refers to the most advanced 3-6 layers 
of tumour cell layers or detached tumour cell groups at 
the invading edge of OSCC, exhibits reduced E-cadherin 
expression compared to the central or superficial tumour 
areas. Moreover, loss of E-cadherin expression at the ITF 
is significantly correlated with poor survival of OSCC 
patients (Wang et al., 2009). 
In 1991, Schipper et al. (1991) described a gradual loss 
of E-cadherin expression with decreasing differentiation 
of OSCC and this finding is reiterated over the years 
with significant results by some authors (Yamada et 
al., 1997; Mahomed et al., 2007; Rosado et al., 2013). 
However, it must be noted that Yamada et al. (1997) had 
few samples from well and poorly differentiated OSCC 
whereas Rosado et al. (2013) only analyzed E-cadherin 
expression between well and moderately differentiated 
OSCC. In fact, the relationship between E-cadherin 
expression and histological grade remains controversial 
with various other studies yielding insignificant results 
(Diniz-Freitas et al., 2006). Rosado et al. (2013) attributed 
these contradicting results to different biologic behaviour 
within the tumour itself or among tumours of different 
sites, despite all head and neck SCCs being the same 
histopathological entity. They have also described an 
association between reduced E-cadherin expression with 
alcohol intake and hypothesized that alcohol may increase 
cancer aggressiveness leading to reduced E-cadherin 
expression. This finding opens up the possibility of other 
as yet untested confounding factors which may influence 
E-cadherin expression in OSCC.
In addition to histological grade, E-cadherin 
immunoexpression has been correlated with various 
clinicopathological variables including primary location, 
clinical stage, depth of tumour invasion, margin status, 
pattern of invasion, treatment options, lymph node 
metastasis, local or regional relapse, disease-free period 
and survival time. Weak expression of E-cadherin has 
been linked to increased invasiveness, shorter disease free 
period and reduced survival rates (Diniz-Freitas et al., 
2006). Menezes et al. (2007) however found E-cadherin 
expression irrelevant when comparing patients with 
SCC of tongue and floor of mouth, with and without 
recurrence during 3 years of follow-up. Nevertheless, a 
recent systemic review and meta-analysis concluded that 
aberrant E-cadherin expression is associated with a poor 
prognosis in head and neck SCC (Zhao et al., 2012).
Existing literature on the prognostic potential of 
E-cadherin expression in relation to lymph node metastasis 
and by default poor prognosis, reveal discordant results. 
Armed with encouraging results, Schipper et al. (1991) 
suggested that E-cadherin expression was inversely 
correlated with lymph node metastasis. They found lymph 
nodes metastasis mostly in cases where the primary 
tumour exhibited negative or heterogenous expression 
of E-cadherin. Expression of E-cadherin was generally 
absent in tumour-infiltrated lymph nodes of patients with 
head and neck SCC. Although later studies managed 
to replicate similar results with regards to the primary 
tumour, E-cadherin expression in the metastatic lymph 
nodes was found to be increased instead (Yamada et al., 
1997; Hung et al., 2006; Zhong et al., 2007). Furthermore, 
Hung et al. (2006) reported a worse prognosis for 
patients with increased E-cadherin expression within 
metastatic lymph nodes. Zhong et al. (2007) suggested 
that “decreased E-cadherin expression of cancerous cells 
in the surface of the cancerous tissue promotes the tumor 
infiltration and invasion into the deeper normal tissue, 
when the shedding cancerous cells from the primary tumor 
stop mechanically and proliferate in the cervical lymph 
node, the E-cadherin expression might play a role on the 
formation of the metastatic focus”. They also concluded 
that E-cadherin may be useful to confirm lymph node 
metastasis but this is doubtful since their study failed to 
detect micrometastasis rendering E-cadherin a subpar 
option compared to cytokeratins. 
In studies which examine the relationship between 
E-cadherin expression in primary tumour and lymph node 
metastasis, results are once again mixed. Several studies 
show positive correlation between E-cadherin expression 
and nodal metastasis (Tanaka et al., 2003; Bosch et al., 
2005; Foschini et al., 2008; Foschini et al., 2013) but 
others including our study, dispute this (Mahomed et al., 
2007; Lopes et al., 2009; Mostaan et al., 2011; Ukpo et 
al., 2012; Rosado et al., 2013). An editorial by Cerezo 
(2011) made an interesting observation; most studies with 
a positive correlation seem to implicate SCC of the oral 
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cavity as opposed to the oropharynx. She suggested that 
biologic difference between oral cavity and oropharynx, 
as well as other dominant prognosticators such as HPV 
status might explain the negative results. We found just 
as many studies with negative results in OSCC alone 
although the sample sizes are admittedly smaller in some 
of these studies. In our study, we also made a conscious 
effort to standardize the tumour site of our samples to 
avoid possible confounding effect even though it has been 
reported that tumour site has no bearing on E-cadherin 
expression (Bosch et al., 2005). Also of interest is the study 
by Mahomed et al. (2007) who reported no significant 
difference of E-cadherin expression at the ITF in patients 
with and without nodal metastasis.
Inconsistent findings have resulted in cautious 
optimism over the use of E-cadherin as a prognostic 
indicator, with most authors favouring further evaluation. 
Consideration of use in combinations with other markers 
such as CD44 (Mostaan et al., 2011), podoplanin (Foschini 
et al., 2013), truncated dominant-negative isoform of p63 
(DNp63) (Foshini et al., 2008), vimentin (Nijkamp et 
al., 2011), α-catenin (Tanaka et al., 2003) and β-catenin 
(Tanaka et al., 2003; Mahomed et al., 2007; Rosado et al., 
2013) is perhaps a more feasible option. 
In conclusion, our study demonstrated a reduction of 
E-cadherin expression in OSCC compared to epithelium 
of normal oral mucosa and reactive lesions. On the other 
hand, Galectin-9 expression conversely increased in 
OSCC compared to epithelium of normal oral mucosa 
and reactive lesions. There was no significant correlation 
between expression of E-cadherin and Galectin-9 with 
lymph node metastasis. Hence, both proteins seem to 
harbour limited potential as prognosticators for OSCC. 
Then again, a trend of higher means for Galectin-9 
HSCORE was noted in OSCC without lymph node 
metastasis compared to OSCC with positive lymph node 
metastasis, suggesting a weak association with a fairer 
prognosis.
However, due to the contrasting results with other 
authors, further studies with a larger sample size and 
possible inclusion of oral potentially malignant lesions 
are necessary to substantiate or disprove our results as 
well as elucidate the molecular aspects on the function 
of Galectin-9 in OSCC. Another limitation of our study 
was the lack of available fresh tissues samples in place 
of the FFPE tissue samples for better and comparable 
IHC results. It would also be interesting to investigate 
the expression of Galectin-9 in OSCC with different 
histological grades in view of the positive correlation of 
Galectin-9 expression with differentiation of SCC in other 
sites (Irie et al., 2005; Liang et al., 2008).
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